14(0.98-1.33) and 1.19(1.03-1.38)(P-trend=0.02). Conclusion: A common genetic variant in NPC1L1, mimicking the effects of ezetimibe on LDL cholesterol, was associated with increased risk of symptomatic gallstone disease and with a trend towards reduced risk of ischemic vascular disease. These results raise the question whether long-term treatment with ezetimibe might increase the risk of symptomatic INCB024360 price gallstone disease. Disclosures:

The following people have nothing to disclose: Bo K. Lauridsen, Stefan Stender, Ruth Frikke-Schmidt, Bøfrge G. Nordestgaard, Anne Tybjærg-Hansen Background / Aim: The secretion of the intestinal hormone FGF19 is induced by binding of bile acid (BA) to the bile acidnuclear farnesoid X receptor (FXR) in the terminal ileum.

On the other side FGF19 suppresses hepatic bile acid biosynthesis. We hypothesized that patients with Crohn΄s disease (CD) show lower FGF19 levels as compared to patients with ulcerative colitis (UC). Patients and Methods: In total, we recruited 12 CD patients after ileocecal resection (ICR), 12 nonoperated CD patients and 12 UC patients as controls in remission. Serum FGF19 levels were determined by ELISA after 10 hrs of overnight fasting. All individuals received orally 1g fat (Calogen®) per kg body weight, and FGF19 levels were measured after 2, 4 and 6 hrs. Serum concentrations of BA and 7α-OHcholesterol levels, which is a valid marker Everolimus manufacturer of BA biosynthesis, were determined by GC-MS after 2, 4 and 6 hrs. Results: Basal FGF19 levels are significantly lower in CD patients (± ICR) as compared to UC patients. The increase of FGF19 levels 2, 4 und 6 hrs after the oral fat load differs between UC and CD (ICR+) patients, with highest levels after 4 hrs in UC patients (p<0.05). CD (ICR+) patients display the lowest FGF19 levels at all time points. Fasting and postprandial levels of BA are not significantly different between CD and UC patients. However at all time points, serum 7α-OH-cholesterol levels are significantly higher in CD (ICR+) in comparison to UCpatients. In the

whole study cohort basal FGF19 and basal 7 α- O H-cholesterol levels are inversely correlated (r=0.397, p=0.017). Conclusions: Low FGF19 levels in CD (± ICR) patients could be the consequence of persistent inflammation and impaired bile acid signaling in the ileum. MCE公司 CD (ICR+) patients display lowest FGF19 levels, consistent with highest 7α-O H-cholesterol levels and lack of repression of BA synthesis. We speculate that this observation results from insufficient intestinal FXR activity in CD. Disclosures: The following people have nothing to disclose: Dana Friedrich, Dieter Luetjohann, Frank Lammert, Christoph Reichel “
“Liver inflammation is greater in nonalcoholic steatohepatitis (NASH) than steatosis, suggesting that immune responses contribute to nonalcoholic fatty liver disease (NAFLD) progression.